ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of “Moderate Buy” by Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $4.60.

Several equities analysts have recently issued reports on ALXO shares. UBS Group started coverage on ALX Oncology in a research report on Friday, March 6th. They set a “buy” rating and a $6.00 price objective for the company. Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of ALX Oncology in a report on Tuesday, March 10th. Finally, Wells Fargo & Company began coverage on ALX Oncology in a report on Thursday, March 19th. They set an “overweight” rating and a $5.00 target price on the stock.

Insider Activity

In other ALX Oncology news, CEO Jason Lettmann sold 12,311 shares of the company’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $2.17, for a total value of $26,714.87. Following the transaction, the chief executive officer owned 293,609 shares of the company’s stock, valued at approximately $637,131.53. This represents a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 21.00% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

A number of large investors have recently bought and sold shares of the business. venBio Partners LLC boosted its holdings in ALX Oncology by 32.8% in the first quarter. venBio Partners LLC now owns 12,884,638 shares of the company’s stock worth $25,834,000 after purchasing an additional 3,184,713 shares in the last quarter. Redmile Group LLC boosted its holdings in ALX Oncology by 143.9% in the first quarter. Redmile Group LLC now owns 7,964,188 shares of the company’s stock worth $15,968,000 after purchasing an additional 4,699,470 shares in the last quarter. Vivo Capital LLC bought a new stake in ALX Oncology during the first quarter valued at about $6,385,000. Orbimed Advisors LLC bought a new stake in ALX Oncology during the first quarter valued at about $5,747,000. Finally, Acadian Asset Management LLC boosted its holdings in ALX Oncology by 16.8% during the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after acquiring an additional 186,883 shares during the period. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Stock Down 1.3%

NASDAQ:ALXO opened at $1.54 on Monday. The company has a market capitalization of $207.22 million, a price-to-earnings ratio of -1.03 and a beta of 0.44. ALX Oncology has a one year low of $0.40 and a one year high of $2.66. The stock has a 50-day simple moving average of $1.85 and a 200 day simple moving average of $1.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.21 and a current ratio of 7.21.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Sell-side analysts predict that ALX Oncology will post -0.66 EPS for the current fiscal year.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.